Earnings per share rose 24% to $3.41, compared to Wall Street's consensus estimate of $2.96, according to FactSet. Revenue for the quarter reached $11.67 billion, well above expectations of $10.91 ...

Quantum computing is shaping up to be the next big investing revolution, and for a very good reason. With the power to solve ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

Google's balance sheet is impressive, with negative long-term debt, $110 billion in cash, and a forward dividend yield of ...

Harvey Jones called on artificial intelligence to help him decide where to invest this year's Stocks and Shares ISA allowance ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Wall Street falls as Trump imposes tariffs, but not as badly as feared The threat of a punishing trade war sent Wall Street ...

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...

Absci Corporation’s ABSI share price has surged by 17.57%, which has investors questioning if this is right time to sell.

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...